Page 160 of 439: studies 1,591 to 1,600 of 4,389, newest first. Back to the psilocybin overview
Carolina Digital Repository August 7, 2020 John D. Mccorvy, R.h.j. Olsen, B.l. Roth
[No abstract available]
August 5, 2020 Sofia Beck 1 citation
Depression and anxiety are debilitating mental health conditions that affect a large portion of the United States. Current pharmacological treatments for these disorders require daily administration, are associated with a number of side effects, and can be ineffective for some. Emerging evidence in novel treatment options may necessitate a shift toward how we treat these psychiatric disorders.
Psychopharmacology August 1, 2020 Theresa M. Carbonaro, Matthew W Johnson, Roland R. Griffiths 51 citations
Although both psilocybin and dextromethorphan (DXM) produce psychedelic-like subjective effects, rates of non-medical use of psilocybin are consistently greater than DXM. New data are presented from a study of psilocybin and DXM relevant to understanding the features of psilocybin subjective effects that may account for its higher rates of non-medical use. Single, acute oral doses of psilocybin...
Journal of Pharmaceutical and Biomedical Analysis July 21, 2020 Izumi Morita, Hiroyuki Oyama, Yuki Kiguchi et al. 17 citations
Development of rapid and reliable immunochemical methods for monitoring psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine; Pyb) and psilocin (dephosphorylated metabolite; Psi), the psychoactive compounds contained within hallucinogenic mushrooms (magic mushrooms), is desirable in order to identify these mushrooms and regulate their illicit use. Because no antibody was publicly available for...
Expert Review of Clinical Pharmacology July 10, 2020 Justin P. Reinert, Kayla N. Colunga, Alexandria Etuk et al. 11 citations
Salvia, kratom, and psilocybin mushrooms may not be an initial consideration when healthcare practitioners are triaging an overdose scenario; however, data from around the world demonstrate an increased use of these agents. While not typically fatal, clinicians must be prepared to assess these as a potential etiology of overdoses and provide appropriate supportive care.
ACS Omega July 1, 2020 Jessica Sable, Tura Patterson, Gary Tarpley et al. 41 citations
A second-generation kilogram-scale synthesis of the psychedelic tryptamine psilocybin has been developed. The synthesis was designed to address several challenges first encountered with the scale-up of previously described literature procedures, which were not optimized for providing consistent yield and purity of products, atom economy, or being run in pilot plant-scale reactors. These...
Neuroimage June 30, 2020 Thomas F. Varley, Robin Carhart-Harris, Leor Roseman et al. 91 citations
Psychedelic drugs, such as psilocybin and LSD, represent unique tools for researchers investigating the neural origins of consciousness. Currently, the most compelling theories of how psychedelics exert their effects is by increasing the complexity of brain activity and moving the system towards a critical point between order and disorder, creating more dynamic and complex patterns of neural...
Human Psychopharmacology: Clinical and Experimental June 23, 2020 Edward James, Thomas L Robertshaw, Mathew Hoskins et al. 29 citations
Abstract Objective Research into psychedelic therapy models has shown promise for the treatment of specific psychiatric conditions. Mystical‐type experiences occasioned by psilocybin have been correlated with therapeutic benefits and long‐term improvements in positive mental outlook and attitudes. This article aims to provide an overview of the topic, highlight strengths and weaknesses in...
bioRxiv (Cold Spring Harbor Laboratory) June 11, 2020 Tim Hirschfeld, Timo Torsten Schmidt 8 citations preprint
Abstract Psilocybin is the active component of magic mushrooms and is well known for its psychoactive properties. Different questionnaires have been developed to systematically quantify altered states of consciousness induced by psychoactive drugs. The aim of this study was to obtain the dose-response relationships of the subjective experiences induced by psilocybin in healthy study...
Open Repository of the University of Porto (University of Porto) June 5, 2020 Rui Pedro Leal Andrade
Background: Psilocybin is a naturally occurring serotonin receptor agonist that can be, more commonly, found in the Psilocybe mushrooms. Consumed by indigenous cultures for millenia, Psilocybin, in the 1960s, was marketed in many countries under the trade name Indocybin, and, before its eventual ban, was safely used as an adjunct to psychotherapy in the treatment of depression and anxiety....